文献速递类风湿关节炎

巴瑞替尼治疗类风湿关节炎的心血管安全性

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2019-05-25

该研究汇总9项类风湿关节炎(RA)临床试验,评估巴瑞替尼的心血管与静脉血栓栓塞事件。安慰剂对照24周内,主要不良心血管事件(MACE)、动脉血栓事件(ATE)和充血性心力衰竭(CHF)发生率与安慰剂组无失衡;4 mg组报告6例深静脉血栓/肺栓塞(DVT/PE),安慰剂组0例,但所有6例均有危险因素。长期扩展数据中2 mg与4 mg组DVT/PE发生率相近,且随时间稳定。

要点

  • 巴瑞替尼治疗RA未发现与MACE、ATE或CHF发生率相关。
  • 4 mg巴瑞替尼组报告6例DVT/PE,安慰剂组0例,所有事件均有危险因素。
  • 长期数据中2 mg与4 mg组DVT/PE发生率相近且随时间稳定。

核心结论

  • 在RA临床试验中,未发现巴瑞替尼治疗与MACE、ATE或CHF发生率之间的关联。
  • 4 mg巴瑞替尼组报告6例DVT/PE而安慰剂组0例,但所有6例均有危险因素。

研究设计与样本

  • 数据汇总自9项RA研究,共3492例患者接受巴瑞替尼,暴露量7860患者年。
  • 安慰剂对照至24周的数据来自6项研究,2 mg与4 mg随机剂量比较来自4项研究及其长期扩展研究。

主要发现

  • 安慰剂对照期MACE发生率:安慰剂0.5/100患者年,4 mg巴瑞替尼0.8/100患者年。
  • 安慰剂对照期ATE发生率:安慰剂0.5/100患者年,4 mg巴瑞替尼0.5/100患者年。
  • 安慰剂对照期CHF宽泛术语发生率:安慰剂4.3/100患者年,4 mg巴瑞替尼2.4/100患者年。
  • 安慰剂对照期DVT/PE:安慰剂组0/1070例,4 mg巴瑞替尼组6/997例,其中2例为严重事件。
  • 2 mg-4 mg扩展数据集DVT/PE发生率:2 mg组0.5/100患者年,4 mg组0.6/100患者年;All-bari-RA数据集为0.5/100患者年且随时间稳定。

临床怎么用

  • 对接受巴瑞替尼治疗的RA患者,应评估静脉血栓栓塞危险因素,尤其使用4 mg剂量时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the frequency of cardiovascular and venous thromboembolic events in clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more than 50 countries for the treatment of moderately-to-severely active rheumatoid arthritis (RA). METHODS: Data were pooled from 9 RA studies. Placebo comparison up to 24 weeks included data from 6 studies. Randomized dose comparison between baricitinib doses of 2 mg and 4 mg used data from 4 studies and from the associated long-term extension study. The data analysis set designated "All-bari-RA" included all baricitinib exposures at any dose. RESULTS: Overall, 3,492 RA patients received baricitinib (7,860 patient-years of exposure). No imbalance compared to the placebo group was seen in the incidence of major adverse cardiovascular events (MACE) (incidence rates [IRs] of 0.5 per 100 patient-years for placebo and 0.8 per 100 patient-years for 4 mg baricitinib), arterial thrombotic events (ATE) (IRs of 0.5 per 100 patient-years for placebo and 0.5 per 100 patient-years for 4 mg baricitinib), or congestive heart failure (CHF) broad term (IRs of 4.3 per 100 patient-years for placebo and 2.4 per 100 patient-years for 4 mg baricitinib). Deep vein thrombosis (DVT)/pulmonary embolism (PE) were reported in 0 of 1,070 patients treated with placebo and 6 of 997 patients treated with 4 mg baricitinib during the placebo-controlled period; these events were serious in 2 of 6 patients, while all 6 had risk factors and 1 patient developed DVT/PE after discontinuation of the study drug. In the 2 mg-4 mg-extended data analysis set, IRs of DVT/PE were comparable between the doses across event types (IRs of 0.5 per 100 patient-years in those receiving 2 mg baricitinib and 0.6 per 100 patient-years in those receiving 4 mg baricitinib). In the All-bari-RA data analysis set, the rates were stable over time, with an IR of DVT/PE of 0.5 per 100 patient-years. CONCLUSION: In RA clinical trials, no association was found between baricitinib treatment and the incidence of MACE, ATE, or CHF. With regard to incidence of DVT/PE, 6 events occurred in patients treated with 4 mg baricitinib, but no cases of DVT/PE were reported in the placebo group. During longer-term evaluation, the incidence of DVT/PE was similar between the baricitinib dose groups, with consistent IR values over time, and this was similar to the rates previously reported in patients with RA.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Taylor PC, Weinblatt ME, Burmester GR, et al. Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. Arthritis Rheumatol. 2019. PMID: 30663869. doi:10.1002/art.40841

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。